ATE368653T1 - Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten - Google Patents

Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten

Info

Publication number
ATE368653T1
ATE368653T1 AT01963732T AT01963732T ATE368653T1 AT E368653 T1 ATE368653 T1 AT E368653T1 AT 01963732 T AT01963732 T AT 01963732T AT 01963732 T AT01963732 T AT 01963732T AT E368653 T1 ATE368653 T1 AT E368653T1
Authority
AT
Austria
Prior art keywords
alkyl
haloalkyl
unsubstituted
oxazolylaryloxyacetic
acid derivatives
Prior art date
Application number
AT01963732T
Other languages
German (de)
English (en)
Inventor
Dawn Brooks
Scott Connor
Samuel Dominianni
Alexander Godfrey
Lann Gossett
Christopher Rito
Allie Tripp
Alan Warshawsky
Leonard Winneroski
Guoxin Zhu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE368653T1 publication Critical patent/ATE368653T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01963732T 2000-08-23 2001-08-23 Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten ATE368653T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22723300P 2000-08-23 2000-08-23

Publications (1)

Publication Number Publication Date
ATE368653T1 true ATE368653T1 (de) 2007-08-15

Family

ID=22852305

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01963732T ATE368653T1 (de) 2000-08-23 2001-08-23 Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten

Country Status (9)

Country Link
US (3) US6982278B2 (enExample)
EP (1) EP1313715B1 (enExample)
JP (1) JP2004509084A (enExample)
AT (1) ATE368653T1 (enExample)
AU (1) AU2001284658A1 (enExample)
CA (1) CA2420178A1 (enExample)
DE (1) DE60129712T2 (enExample)
ES (1) ES2288982T3 (enExample)
WO (1) WO2002018355A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
DE60129712T2 (de) * 2000-08-23 2008-07-03 Eli Lilly And Co., Indianapolis Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
ES2295200T3 (es) 2000-08-23 2008-04-16 Eli Lilly And Company Derivados de acido oxazolil-arilpropionico y su uso como agonistas de ppar.
CA2418104A1 (en) 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
US7105551B2 (en) 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
EA200400011A1 (ru) * 2001-06-07 2004-06-24 Эли Лилли Энд Компани Модуляторы рецепторов, активируемых пролифераторами пероксисом (prar)
US20110065129A1 (en) 2001-07-27 2011-03-17 Lowe Derek B Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
AR036237A1 (es) * 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
ITRM20020014A1 (it) * 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del
DE60324898D1 (de) 2002-02-25 2009-01-08 Lilly Co Eli Modulatoren von peroxisome proliferator-aktivierten rezeptoren
JP2005529077A (ja) 2002-02-25 2005-09-29 イーライ・リリー・アンド・カンパニー ペルオキシソーム増殖因子活性化受容体調節物質
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6867224B2 (en) * 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
UA79755C2 (en) * 2002-04-16 2007-07-25 Bayer Pharmaceuticals Corp Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
WO2004011446A1 (en) * 2002-07-26 2004-02-05 Bayer Pharmaceuticals Corporation Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics
US7129268B2 (en) * 2002-10-28 2006-10-31 Novo Nordisk A/S Peroxisome proliferator activated receptor-active arylene acetic acid derivatives
ES2295692T3 (es) * 2002-11-08 2008-04-16 F. Hoffmann-La Roche Ag Nuevos derivados de 4-alcoxioxazol sustituido como agonistas de ppar.
US7192970B2 (en) * 2002-11-26 2007-03-20 Chipscreen Biosciences, Ltd. Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity
CA2512883A1 (en) 2003-02-14 2004-09-02 Eli Lilly And Company Sulfonamide derivatives as ppar modulators
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
CN100398536C (zh) * 2003-08-20 2008-07-02 爱密斯菲尔科技公司 用于口服传递glp-1化合物或mc4激动剂肽的化合物、方法和制剂
JP4767850B2 (ja) 2003-08-20 2011-09-07 エミスフィアー テクノロジーズ インコーポレイテッド グルカゴン様ペプチド(glp)−1化合物またはメラノコルチン4受容体(mc4)アゴニストペプチドの経口デリバリーのための化合物、方法および製剤
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
WO2005049572A1 (en) * 2003-11-05 2005-06-02 F. Hoffmann-La Roche Ag Benzannelated compounds as ppar activators
WO2005049573A1 (en) * 2003-11-05 2005-06-02 F. Hoffmann-La Roche Ag Phenyl derivatives as ppar agonists
ES2347578T3 (es) * 2004-05-05 2010-11-02 High Point Pharmaceuticals, Llc Derivados del acido fenoxiacetico como agonistas de ppar.
EP1745014B1 (en) * 2004-05-05 2011-07-06 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
JP2007284352A (ja) * 2004-08-05 2007-11-01 Dai Ichi Seiyaku Co Ltd ピラゾール誘導体
WO2006108491A1 (en) * 2005-04-11 2006-10-19 Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg Improved process for preparing oxazole nitriles
EA201101084A1 (ru) * 2005-12-22 2012-04-30 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Феноксиуксусные кислоты в качестве активаторов ppar дельта
JO3598B1 (ar) * 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
AU2009233711B2 (en) * 2008-04-09 2015-02-12 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
EP2416660B1 (en) 2009-04-07 2014-07-02 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
EP2531511A1 (en) * 2010-02-03 2012-12-12 Infinity Pharmaceuticals, Inc. Fatty acid amide hydrolase inhibitors
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
CN104230836B (zh) * 2014-09-29 2016-08-31 中国科学院成都生物研究所 苯基噁唑类化合物及在制备治疗癌症的药中的应用
DK3362462T3 (da) 2015-10-12 2021-10-11 Advanced Cell Diagnostics Inc In situ-detektion af nukleotidvarianter i prøver med højt støjniveau, og sammensætninger og fremgangsmåder relateret dertil
CA3185909A1 (en) 2020-07-22 2022-01-27 Reneo Pharmaceuticals, Inc. Crystalline ppar-delta agonist
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
US5902726A (en) 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
JPH08325250A (ja) * 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規置換フェノール誘導体
DE69723680T9 (de) 1996-02-02 2004-11-04 Merck & Co., Inc. Antidiabetische mittel
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
IL128600A0 (en) 1996-08-19 2000-01-31 Japan Tobacco Inc Propionic acid derivatives and pharmaceutical compositions containing them
JP4345230B2 (ja) 1998-03-10 2009-10-14 小野薬品工業株式会社 カルボン酸誘導体およびその誘導体を有効成分として含有する薬剤
US6121300A (en) * 1998-11-10 2000-09-19 Wagle; Dilip R. Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts
DK1206457T3 (da) * 1999-08-27 2004-02-16 Lilly Co Eli Biaryl-oxa(thia)zolderivater og deres anvendelse som modulatorer PPAP'ER
JP4316787B2 (ja) * 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
DE60129712T2 (de) * 2000-08-23 2008-07-03 Eli Lilly And Co., Indianapolis Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
ES2295200T3 (es) 2000-08-23 2008-04-16 Eli Lilly And Company Derivados de acido oxazolil-arilpropionico y su uso como agonistas de ppar.
CA2418104A1 (en) 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

Also Published As

Publication number Publication date
JP2004509084A (ja) 2004-03-25
US6982278B2 (en) 2006-01-03
US20050250825A1 (en) 2005-11-10
DE60129712T2 (de) 2008-07-03
CA2420178A1 (en) 2002-03-07
DE60129712D1 (de) 2007-09-13
US7351728B2 (en) 2008-04-01
AU2001284658A1 (en) 2002-03-13
US20080146631A1 (en) 2008-06-19
EP1313715A1 (en) 2003-05-28
US20040024034A1 (en) 2004-02-05
EP1313715B1 (en) 2007-08-01
WO2002018355A1 (en) 2002-03-07
ES2288982T3 (es) 2008-02-01

Similar Documents

Publication Publication Date Title
DE60129712D1 (de) Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
CY1107679T1 (el) Παραγωγα οξαζολυλ-αρυλ προπιονικου οξεος και χρηση αυτων σαν αγωνιστες ppar
PE20000625A1 (es) Derivados de acido oxiiminoalcanoico
DK0976748T3 (da) Pyrrolidinderivater med phospholispase A2-hæmmende aktivitet
DE69725113D1 (de) Azetidin- und Pyrrolidinderivate
DK1178982T3 (da) Heterocykliske, substituerede aminoazacykliske forbindelser, der er nyttige som midler til centralnervesystemet
DE69327944D1 (de) Thiazolidindione-Derivate, ihre Herstellung und Verwendung
DK1008592T3 (da) Cykliske amidderivater, som inhiberer cathepsin K
DE69509452D1 (de) Tetrazolinon-Herbizide
ATE173256T1 (de) Azolidindion-derivate und ihre anwendung als antihyperglykämika
ATE466861T1 (de) Aminderivate
NO20072753L (no) 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer
NO307087B1 (no) 3-(hetero)arylkarboksylsyrederivater, midler inneholdende dem, anvendelse av dem og mellomprodukter i deres fremstilling
DE602006008320D1 (de) Pyrrolopyridin-derivate und deren verwendung als ppar-rezeptormodulatoren
EA200200470A1 (ru) Новые производные тиазолидиндиона в качестве противодиабетических средств
MXPA02003952A (es) Derivados de imidazol como inhibidores de la fosfodieterasa vii.
NZ309499A (en) Styryl benzimidazole derivatives useful as inhibitors of smooth muscle cell proliferation
WO2007068815A3 (fr) Derives heterocycliques, leur preparation et leur application en therapeutique.
ATE235450T1 (de) 2-indanmethanolderivate und ihre verwendung als riechstoffe
ATE405555T1 (de) Medizinische zusammensetzung, die ein 1,3- thiazinderivat enthält
NO20020886L (no) Nye integrin- <alfa>v<beta>3-inhibitorer
NO20002575L (no) Substituerte oksimer som neurokininantagonister
CA2258960A1 (en) A process for preparing naphthyridones and intermediates
DE60333095D1 (de) Imidazolverbindungen und ihre verwendung als alpha-2 adrenorezeptorliganden

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties